

Dr. Nayyereh Ayati
Centre for Health Economics
Email: Ney.Ayati@monash.edu



Biography

Nayyereh is an accomplished pharmacist and pharmacoeconomist, leveraging her educational background to drive impactful research and contribute to the field of healthcare. With a proven track record in conducting health technology assessments and health policy research, she is dedicated to improving patients' access to efficient treatment strategies. Currently serving as a research fellow at the **Centre for Health Economics** at the **Monash Business School**, Nayyereh continues to explore innovative approaches to enhance healthcare outcomes and advance evidence-based decision-making in the field.

Qualifications

Pharmacoeconomics and Pharmaceutical Administration, PhD, Tehran University of Medical Sciences
21 Jan 2016 → 15 Jan 2022

Pharmacy, Pharmaceutical Doctorate (PharmD), Mashhad University of Medical Sciences
23 Sept 2009 → 15 Jan 2016

Employment

Research Fellow

Centre for Health Economics
MONASH UNIVERSITY
29 May 2023 → present

Visiting Researcher

Peter MacCallum Cancer Centre
Melbourne, Australia
1 Oct 2022 → 1 Dec 2022

Health Economics & Outcome Research Advisor

Cobel Group
Tehran, Iran
1 Aug 2018 → 1 May 2023

Assistant University Lecturer

Ardabil University of Medical Sciences
Ardabil, Iran
1 Oct 2017 → 1 Jan 2021

Assistant University Lecturer

Tehran University of Medical Sciences
Tehran, Iran
1 Oct 2017 → 1 Jan 2021

Business Development Specialist

Pars Darou Pharmaceutical Company
Tehran, Iran
1 Sept 2017 → 1 Sept 2018

Internship

Iran Food and Drug Administration

Tehran, Iran

1 Apr 2016 → 1 Apr 2017

Responsible Pharmacist

Tehran University of Medical Sciences

Tehran, Iran

1 Jan 2013 → 1 Jan 2018

Research outputs

Radiotherapy and theranostics: a *Lancet Oncology* Commission

Abdel-Wahab, M., Giamarile, F., Carrara, M., Paez, D., Hricak, H., Ayati, N., Li, J. J., Mueller, M., Aggarwal, A., Al-Ibraheem, A., Alkhatib, S., Atun, R., Bello, A., Berger, D., Delgado Bolton, R. C., Buatti, J. M., Burt, G., Bjelac, O. C., Cordero-Mendez, L. & Dosanjh, M. & 32 others, Eichler, T., Fidarova, E., Gondhowiardjo, S., Gospodarowicz, M., Grover, S., Hande, V., Harsdorf-Enderndorf, E., Herrmann, K., Hofman, M. S., Holmberg, O., Jaffray, D., Knoll, P., Kunikowska, J., Lewis, J. S., Lievens, Y., Mikhail-Lette, M., Ostwald, D., Palta, J. R., Peristeris, P., Rosa, A. A., Salem, S. A., dos Santos, M. A., Sathekge, M. M., Shrivastava, S. K., Titovich, E., Urbain, J. L., Vanderpuye, V., Wahl, R. L., Yu, J. S., Zaghloul, M. S., Zhu, H. & Scott, A. M., Nov 2024, In: *The Lancet Oncology*. 25, 11, p. e545-e580 36 p.

Production and regulatory issues for theranostics

Giamarile, F., Paez, D., Zimmermann, R., Cutler, C. S., Jalilian, A., Korde, A., Knoll, P., Ayati, N., Lewis, J. S., Lapi, S. E., Delgado Bolton, R. C., Kunikowska, J., Estrada Lobato, E., Urbain, J.-L., Holmberg, O., Abdel-Wahab, M. & Scott, A. M., Jun 2024, In: *The Lancet Oncology*. 25, 6, p. e260-e269 10 p.

Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics

Scott, A. M., Zeglis, B. M., Lapi, S. E., Scott, P. J. H., Windhorst, A. D., Abdel-Wahab, M., Giamarile, F., Paez, D., Jalilian, A., Knoll, P., Korde, A., Vichare, S., Ayati, N., Lee, S. T., Lyashchenko, S. K., Zhang, J., Urbain, J. L. & Lewis, J. S., Jun 2024, In: *The Lancet Oncology*. 25, 6, p. e250-e259 10 p.

Economic analysis of 177Lu-PSMA-I&T in Australian patients with metastatic castration-resistant prostate cancer
Ayati, N., Nov 2023, In: *Internal Medicine Journal*. 53, S4, 1 p.

The cost-effectiveness analysis of Ozanimod in comparison to Fingolimod in Iran

Ayati, N., Faraji, H., Dezfoliyan, S. & Sahraian, M. A., Mar 2023, In: *Multiple Sclerosis and Related Disorders*. 71, p. 33 1 p., 104346.

Cost-effectiveness comparison between Ticagrelor and Clopidogrel in acute coronary syndrome in Iran

Hashemi-Meshkini, A., Tajik, A., Ayati, N., Nikfar, S., Koochak, R., Yaghoubifard, S., Abbasi, A. & Varmaghani, M., 2023, In: *Journal of Tehran University Heart Center*. 18, 2, p. 94-101 8 p.

Precision medicine journey through omics approach

Hasanzad, M., Sarhangi, N., Ehsani Chimeh, S., Ayati, N., Afzali, M., Khatami, F., Nikfar, S. & Aghaei Meybodi, H. R., Jun 2022, In: *Journal of Diabetes and Metabolic Disorders*. 21, 1, p. 881-888 8 p.

Cost-effectiveness of empagliflozin compared to liraglutide in Iran based on cardiovascular outcome trials in type 2 Diabetes Mellitus

Ayati, N., Layeghi-Ghalehsoukhteh, S. & Esteghamati, A., 2022, In: *Journal of Pharmacoeconomics and Pharmaceutical Management*. 8, 1/2, p. 24-30 7 p.

س اسا رب ى دربراک-ى فیک ى شهوزب: ناریا رد س کیمون زوکامراف ىورشیپ ىاهیگدیچیپ اب طبترم ىم و هفم لدم هی ارا ىیوراد ىلم تسايس ىاههفلوم

Ayati, N., Afzali, M., Hasanzad, M., Kebriaeezadeh, A., Ghatari, A. R. & Nikfar, S., 2022, In: *Koomesh*. 24, 2, p. 245-254 10 p.

Pharmacogenomics implementation and hurdles to overcome; in the context of a developing country
Ayati, N., Afzali, M., Hasanzad, M., Kebriaeezadeh, A., Rajabzadeh, A. & Nikfar, S., Oct 2021, In: Iranian Journal of Pharmaceutical Research. 20, 4, p. 92-106 15 p.

Cladribine tablets are a cost-effective strategy in high-disease activity relapsing multiple sclerosis patients in Iran
Ayati, N., Fleifel, L., Sharifi, S., Sahraian, M. A. & Nikfar, S., Jul 2021, In: Current Journal of Neurology. 20, 3, p. 146-153 8 p.

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
Ayati, N., Taheri, S., Sahraian, M. A. & Nikfar, S., Jul 2021, In: Current Journal of Neurology. 20, 3, p. 154-161 8 p.

A systematic review and economic evaluation of sumatriptan nasal spray versus its oral tablet
Alipour Haris, G. & Ayati, N., 2021, In: Journal of Pharmacoeconomics and Pharmaceutical Management. 7, 3/4, p. 61-69 9 p.

Correlation between divided doses of chronic antihypertensive drugs and pregnancy outcomes
Dehno, S. H., Taghavi, S. & Ayati, N., Jul 2020, In: International Journal of Women's Health and Reproduction Sciences. 8, 3, p. 328-332 5 p.

Cladribine tablets are a cost-effective and cost-saving treatment strategy for high disease activity relapsing multiple sclerosis patients in Iran
Ayati, N., Fleifel, L., Sharifi, S., Sahraian, M. A. & Nikfar, S., Jan 2020, In: Multiple Sclerosis and Related Disorders. 37, 1 p., 101577.

Short and long term impacts of COVID-19 on the pharmaceutical sector
Ayati, N., Saiyarsarai, P. & Nikfar, S., 2020, In: DARU Journal of Pharmaceutical Sciences. 28, 2, p. 799-805 7 p.

PND45 Ocrelizumab is a cost-effective option for relapsing multiple sclerosis patients, in Iran
Ayati, N., Sahraian, M., Taheri, S. & Nikfar, S., Nov 2019, In: Value in Health. 22, S3, p. S744-S745 2 p.

PND47 Cladribine tablet, as a dominant comparator to Natalizumab in high-disease activity relapsing multiple sclerosis patients, in the context of a developing country
Ayati, N., Fleifel, L., Sharifi, S., Sahraian, M. A. & Nikfar, S., Nov 2019, In: Value in Health. 22, S3, p. S745 1 p.

Comparison of treatment response achieved by tablet splitting versus whole tablet administration of Levothyroxine in patients with thyroid cancer
Ashrafpour, R. & Ayati, N., 2018, In: Asia Oceania Journal of Nuclear Medicine and Biology. 6, 2, p. 108-112 5 p.

Evaluation of serum Asymmetric Dimethyl Arginine concentrations in coronary artery disease patients without traditional cardiovascular risk factors
Ghayour-Mobarhan, M., Ayati, N., Sahebkar, A. H., Moohebati, M., Ayati, N., Elyasi, S. & Mohammadpour, A. H., 2018, In: Acta Biomedica. 89, 2, p. 203-208 6 p.

A cost minimization analysis of Azelastine/Fluticasone combination nasal spray versus azelastine and fluticasone nasal sprays monotherapy in moderate to severe allergic rhinitis: an experience from Islamic Republic of Iran
Zaboli, P., Nikfar, S., Ayati, N., Rohani, E., Toroski, M. & Babaei, D., Oct 2017, In: Value in Health. 20, 9, p. A647 1 p.

Evaluation of health care reform impact on cancer patients total out of pocket: a pilot-center experience in Islamic Republic of Iran
Sarkhanloo, F., Zaboli, P., Saeedi, M., Janbabai, G., Nikfar, S., Morteza-Semnani, K., Rohani, E. & Ayati, N., Oct 2017, In: Value in Health. 20, 9, p. A880 1 p.

A cost minimization analysis of Azelastine/Fluticasone combination nasal spray versus Azelastine and Fluticasone nasal sprays monotherapy in moderate to severe allergic rhinitis in Iran
Ayati, N., Babaie, D., Nikfar, S., Rohani, E., Nosrati, M. & Zaboli, P., 2017, In: Journal of Pharmacoconomics and Pharmaceutical Management. 3, 1/2, p. 21-23 3 p.